Companies › Adcendo ApS
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ADCE-B05 Antibody-drug conjugate | – | Phase 1 | Solid Tumors (Phase 1) | Dec 2026 |
| ADCE-T02 Tissue factor targeted antibody-drug conjugate | F3 | Phase 1 | Advanced Solid Tumor | Mar 2027 |
| ADCE-D01 anti-uPARAP antibody conjugated to topoisomerase I inhibitor via protease-cleavable linker | PLAUR | Phase 1 | Metastatic Soft Tissue Sarcoma | Feb 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07362888 | ADCE-B05 | Phase 1 | Solid Tumors (Phase 1) | Oncology | Dec 2026 |
| NCT06597721 | ADCE-T02 | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2027 |
| NCT06797999 | ADCE-D01 | Phase 1 | Metastatic Soft Tissue Sarcoma | Oncology | Feb 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.